Conclusion of non-exclusive discount agreements pursuant to § 130a(8) SGB V on medicinal products (open-house procedure) Text automatically translated in your browsing language Automatically translated

The present procedure is not subject to public procurement law. This is an open-house procedure. In the interests of transparency and the broadest possible information for interested pharmaceutical companies, this notice shall be published in the Supplement to the Official Journal of the European Union. Insofar as formulations are used in the context of this notice that indicate the award of a public contract, this is solely due to the requirements of this notice form. This and the use of the medium "TED" are not subject to public procurement regulations, the validity of which is not prescribed by law or public procurement regulations and according to the case-law of the European Court of Justice. This open house procedure was published on 21.4.2023 in the Supplement to the Official Journal of the EU (OJ No. EU 2023/S 079-237358) published for the first time (the so-called First Notice). The AOK Baden-Württemberg (AOK) has identified the procurement needs for this procedure with OJ EU 2023/S 106-334083 (first follow-up notice), OJ EPO 2023, p. EU 2024/S 023-67957 (second follow-up notice), OJ No. EU 2024/S 67-199292 (third follow-up notice), OJ No. EU 2024/S 121-372200 (Fourth Follow-up Notice), OJ L 149, 20.12.1924, p. EU 2024/S 163-503369 (fifth Consequences Notice), OJ EPO 2024, p. EU 2024/S 191-589829 (sixth Consequences Notice) and OJ EU 2024/S 213-665386 extended. AOK intends to conclude non-exclusive discount agreements with all suitable pharmaceutical companies in accordance with § 130a(8) SGBV on medicinal products with the active substances specified in Annex 3 to the conditions of participation. The duration of the contract for the active substances referred to in Section II.2.4) of the initial notification (so-called starting substances) shall not start until 1.7.2023 at the earliest and shall not exceed 24 months. The duration of the contract for the combination of active substances referred to in Section II.2.4) of the first subsequent notice shall not be earlier than 1.8.2023 and shall not exceed 23 months. The duration of the contract for the active substance referred to in point 5.1 of the second subsequent notice shall not be earlier than 1.3.2024 and shall not exceed 15 months. The duration of the contract for the active substance referred to in point 5.1 of the third subsequent notice shall not be earlier than 1.7.2024 and shall not exceed 12 months. The duration of the contract for the active substances referred to in point 5.1 of the fourth follow-up notice shall not be earlier than 1.9.2024 and shall not exceed 10 months. The duration of the contract for the active substance referred to in point 5.1 of the fifth subsequent notice shall not be earlier than 1.11.2024 and shall not exceed 8 months. The duration of the contract for the active substance referred to in point 5.1 of the sixth follow-up notice shall not be earlier than 1.12.2024 and shall not exceed 7 months. The duration of the contract for the active substances referred to in point 5.1 of the seventh follow-up notice shall not be earlier than 1.1.2025 and shall not exceed 6 months. The contract period ends at the latest on 30/06/2025. A contract can be concluded at any time within the period from 1.7.2023 or 1.8.2023 or 1.4.2024 or 1.7.2024 or 1.9.2024 or 1.11.2024 or 1.12.2024 or 1.1.2025 to 30.6.2025 at the first of a month. Exact order values cannot be determined because they depend on various unknown factors. The contract values for the awarded contracts can therefore only be specified as fictitious values based on the currently applicable threshold values. Text automatically translated in your browsing language Automatically translated

33600000 - Pharmaceutical products